Loading stock data...

Supriya Lifescience Limited

NSE: SUPRIYA BSE: SUPRIYA

NSE
689.50 -10.25 (-1.46%)

Prev Close

699.75

Open Price

699

Volume

186,457

Today Low / High

686.7 / 704.9

52 WK Low / High

380 / 842

Range

655 - 724

BSE
690.70 -8.65 (-1.24%)

Prev Close

699.35

Open Price

690.35

Volume

10,956

Today Low / High

686.15 / 702.25

52 WK Low / High

376.15 / 841.7

Range

656 - 725

The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 689.5 (target range: 655 - 724), reflecting a change of -10.25 (-1.46481%). On the BSE, it is listed at 690.7 (target range: 656 - 725), showing a change of -8.65 (-1.23686%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.

23 Jul 698.00 0.25%
22 Jul 697.00 -0.44%
21 Jul 711.75 -1.92%
18 Jul 720.30 -1.25%
17 Jul 720.00 0.04%
16 Jul 727.00 -0.85%
15 Jul 720.00 0.56%
14 Jul 690.00 3.60%
11 Jul 692.50 -0.70%
10 Jul 711.50 -2.54%
09 Jul 708.75 0.06%
08 Jul 715.55 -1.56%
07 Jul 742.65 -3.89%
04 Jul 722.00 1.84%
03 Jul 729.35 -0.46%
02 Jul 720.00 0.79%
01 Jul 711.75 1.79%
30 Jun 688.75 2.95%
27 Jun 683.20 0.82%

Supriya Lifescience Limited Graph

Supriya Lifescience Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Supriya Lifescience Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 689.50, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 690.70 697.61 627.85 - 767.37
704.51 563.61 - 845.42
711.42 497.99 - 924.85
Bearish Scenario 690.70 683.79 615.41 - 752.17
676.89 541.51 - 812.26
669.98 468.99 - 870.97

Overview of Supriya Lifescience Limited

ISIN

INE07RO01027

Industry

Biotechnology

Vol.Avg

266,388

Market Cap

56,317,839,300

Last Dividend

0.8

Official Website

Visit Website

IPO Date

2021-12-28

DCF Diff

701.53

DCF

-2

Financial Ratios Every Investor Needs

Stock Dividend of SUPRIYA

Date Label Adj Dividend Dividend Record Date Payment Date Declaration Date
2024-09-20 September 20, 24 0.8 0.8 2024-09-20 2024-10-27
2023-09-15 September 15, 23 0.6 0.6 2023-09-15 2023-10-29
2022-09-01 September 01, 22 0.6 0.6 2022-09-02 2022-10-16

Stock Rating Details for SUPRIYA

Metric Value Recommendation
Overall Rating B Neutral
DCF Score 1 Strong Sell
ROE Score 5 Strong Buy
ROA Score 5 Strong Buy
Debt-to-Equity (DE) Score 4 Buy
Price-to-Earnings (PE) Score 1 Strong Sell
Price-to-Book (PB) Score 1 Strong Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 696.49 Cr 312.14 Cr 384.35 Cr 0.5518 0.00 Cr 0.00 Cr 240.35 Cr 187.96 Cr 23.35 270.61 Cr 0.2699
2024-03-31 557.44 Cr 277.19 Cr 280.25 Cr 0.5027 1.09 Cr 23.19 Cr 157.17 Cr 119.11 Cr 14.80 183.58 Cr 0.2137
2023-03-31 460.94 Cr 180.81 Cr 280.13 Cr 0.6077 1.24 Cr 19.23 Cr 117.17 Cr 89.86 Cr 11.16 138.39 Cr 0.1949
2022-03-31 519.37 Cr 229.89 Cr 289.49 Cr 0.5574 1.66 Cr 13.73 Cr 204.34 Cr 151.81 Cr 18.86 221.56 Cr 0.2923
2021-03-31 385.37 Cr 151.17 Cr 234.20 Cr 0.6077 0.66 Cr 10.52 Cr 166.39 Cr 123.59 Cr 16.89 178.15 Cr 0.3207

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 79.15 Cr 1,112.31 Cr 115.56 Cr 996.7600 Cr 5.38 Cr -73.77 Cr 118.35 Cr 599.49 Cr 0.00 Cr 0.00 Cr 63.24 Cr 82.1620 Cr
2024-03-31 68.17 Cr 921.24 Cr 105.87 Cr 815.3660 Cr 5.49 Cr -62.68 Cr 85.25 Cr 457.30 Cr 14.87 Cr 0.00 Cr 63.80 Cr 76.8940 Cr
2023-03-31 85.25 Cr 820.28 Cr 120.82 Cr 699.4590 Cr 22.47 Cr -62.78 Cr 115.77 Cr 328.06 Cr 1.66 Cr 0.00 Cr 25.30 Cr 95.7800 Cr
2022-03-31 165.78 Cr 734.76 Cr 119.08 Cr 615.6880 Cr 27.42 Cr -138.36 Cr 92.31 Cr 231.67 Cr 25.45 Cr 2.93 Cr 0.05 Cr 99.6990 Cr
2021-03-31 31.07 Cr 445.82 Cr 176.88 Cr 268.9420 Cr 72.19 Cr 41.12 Cr 72.48 Cr 175.92 Cr 17.60 Cr 20.79 Cr 0.05 Cr 146.0190 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 172.5650 Cr -161.8200 Cr -6.5470 Cr 10.1890 Cr 0.0000 Cr 79.1540 Cr -162.3760 Cr 187.9580 Cr 0.0000 Cr -6.4390 Cr -33.1000 Cr
2024-03-31 113.3070 Cr -173.5750 Cr -22.3590 Cr -32.3480 Cr -82.6260 Cr 74.9560 Cr -145.6550 Cr 119.1140 Cr -16.6250 Cr -4.8290 Cr 30.5210 Cr
2023-03-31 66.1870 Cr -133.1450 Cr -3.3680 Cr -42.2130 Cr -70.3260 Cr 157.5820 Cr -108.4000 Cr 123.4870 Cr -4.6700 Cr -4.8290 Cr -23.4580 Cr
2022-03-31 48.8010 Cr -59.8220 Cr 149.6520 Cr -11.1030 Cr 138.6310 Cr 227.9080 Cr -59.9040 Cr 207.2450 Cr -0.7630 Cr -4.3910 Cr -19.8320 Cr
2021-03-31 79.9300 Cr -47.4100 Cr -14.9310 Cr 31.6890 Cr 17.5880 Cr 92.2930 Cr -48.2410 Cr 167.3930 Cr -11.6660 Cr -3.9560 Cr -23.0220 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-03-31 184.11 Cr 81.88 Cr 102.23 Cr 0.5552 61.50 Cr 50.38 Cr 6.29 70.56 Cr 0.2737
2024-12-31 185.65 Cr 61.78 Cr 123.87 Cr 0.6672 60.99 Cr 46.78 Cr 5.82 68.05 Cr 0.2520
2024-09-30 166.10 Cr 70.40 Cr 95.70 Cr 0.5761 59.97 Cr 46.15 Cr 5.71 67.24 Cr 0.2778
2024-06-30 160.63 Cr 73.34 Cr 87.29 Cr 0.5434 57.89 Cr 44.64 Cr 5.55 64.77 Cr 0.2779
2024-03-31 158.18 Cr 79.32 Cr 78.86 Cr 0.4986 51.59 Cr 36.93 Cr 4.59 57.69 Cr 0.2335

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-03-31 79.15 Cr 0.00 Cr 79.15 Cr 134.36 Cr 118.35 Cr 437.04 Cr 599.49 Cr 1,112.31 Cr 115.56 Cr
2024-12-31 0.00 Cr 0.00 Cr 84.31 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -905.89 Cr
2024-09-30 77.51 Cr 9.46 Cr 86.96 Cr 105.73 Cr 107.99 Cr 413.36 Cr 522.68 Cr 1,012.39 Cr 106.50 Cr
2024-06-30 0.00 Cr 0.00 Cr 74.96 Cr 0.00 Cr 0.00 Cr 74.96 Cr 0.00 Cr 0.00 Cr -815.37 Cr
2024-03-31 74.96 Cr 11.12 Cr 74.96 Cr 111.68 Cr 85.25 Cr 397.80 Cr 457.30 Cr 921.24 Cr 105.87 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2024-12-31 46.78 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 46.15 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 44.64 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-03-31 36.93 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2023-12-31 29.79 Cr 7.92 Cr 0.00 Cr 0.00 Cr 7.92 Cr 111.96 Cr 104.04 Cr 0.00 Cr 7.92 Cr

Splits History

Date Label Split Ratio
No split history data available.

Similar Stocks: Biotechnology

Company Name Symbol Price Market Cap Volume
Biocon Limited BIOCON ₹397.60 ₹530,566,615,813.00 ₹3,141,801.00
Piramal Pharma Limited PPLPHARMA ₹203.19 ₹270,089,941,758.00 ₹2,833,824.00
Syngene International Limited SYNGENE ₹669.75 ₹268,814,137,757.00 ₹2,108,488.00
Concord Biotech Limited CONCORDBIO ₹1,928.40 ₹201,741,880,080.00 ₹180,393.00
Blue Jet Healthcare Limited BLUEJET ₹812.05 ₹140,862,594,311.00 ₹3,390,634.00
Jubilant Ingrevia Limited JUBLINGREA ₹819.20 ₹130,482,995,200.00 ₹282,311.00
Supriya Lifescience Limited SUPRIYA ₹689.50 ₹55,492,890,600.00 ₹186,457.00
Dishman Carbogen Amcis Limited DCAL ₹253.55 ₹39,752,329,650.00 ₹85,916.00
Zota Health Care Limited ZOTA ₹1,195.10 ₹35,211,828,850.00 ₹22,483.00
Panacea Biotec Limited PANACEABIO ₹434.15 ₹26,591,991,405.00 ₹128,867.00

Key Executives

Whole-time Director
Ms. Smita Satish Wagh

Gender: female

Year Born: 1958

Company Secretary & Compliance Officer
Ms. Prachi Sathe

Gender: female

Year Born:

Managing Director
Dr. Saloni Satish Wagh

Gender: Not Specified

Year Born: 1990

Whole Time Director
Mr. Balasaheb Gulabrao Sawant

Gender: male

Year Born: 1964

Chief Financial Officer
Mr. Krishna Raghunathan

Gender: male

Year Born:

Head of Corporate Quality Assurance & Regulatory Affairs
Dr. Prashant Baban Zate

Gender: Not Specified

Year Born:

Founder, Executive Chairman & Whole Time Director
Dr. Satish Waman Wagh

Gender: Not Specified

Year Born: 1955

Chief Scientific Officer
Dr. Sushanta Kumar Gouranga Mishra

Gender: Not Specified

Year Born:

Joint Managing Director
Ms. Shivani Satish Wagh

Gender: female

Year Born: 1991

Technical Head
Dr. Shireesh Bhalchandra Ambhaikar

Gender: Not Specified

Year Born:

FAQs about Supriya Lifescience Limited

Who is the CEO of the company?

The CEO is Satish Waman Wagh.

What is the current market price of the stock?

The current price is ₹699.75.

What is the 52-week price range?

The range is ₹380-842.

What is the market capitalization of the company?

The market capitalization is ₹5,631.78 crores.

What is the dividend yield?

The dividend yield is 0.11%.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 29.99.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Supriya Lifescience Limited (ISIN: INE07RO01027) is a leading Biotechnology in India. With a market capitalization of ₹5,631.78 crores and an average daily volume of 266,388 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.8.

Welcome to the Investing and Trading Information platform: InvesTrack.in

Note: This platform is for educational and informational purposes only. Do not consider anything as financial advice.

QUICK LINKS

Home
About us
Contact us
Privacy Policy
Disclaimer
Sitemap
Investing
Trading
Top Brokers
Tools
Live Analysis

STAY CONNECTED

Follow Us On Social Media
Get Latest Update On Social Media
Facebook Instagram Twitter

General Disclaimer: InvesTrack is an educational platform and not any type of investment advisory platform. Our Blog and videos are based on countless hours of research and experience, which you can use as a guide for your research purposes. None of our content should be considered a piece of investment advice. Earning Disclosure: InvesTrack is a community supported platform. We may earn a commission when you make a purchase through one of our links at no extra cost to you. Note: We are not SEBI Registered Advisors. This website is purely for training and educational purposes. We shall not be responsible for your profit or loss.

© Copyright 2024 - 2025 | InvesTrack